Amgen

What Amgen does

Amgen is one of the world's largest independent biotechnology companies, founded in 1980 and headquartered in Thousand Oaks, California. It discovers, develops, manufactures, and commercializes biologic medicines—therapeutic proteins produced using living cells—for serious illnesses across general medicine (cardiovascular, bone health, obesity), rare disease, inflammation, and oncology. Its platform combines human genetic data assets (via the deCODE Genetics acquisition), proprietary machine learning models (e.g., protein viscosity prediction from amino acid sequences), and generative biology approaches to drug discovery. Core commercial products include six franchises each exceeding $1 billion in annual revenue: Repatha (cardiovascular), Prolia/XGEVA (bone), Enbrel (inflammation), BLINCYTO and IMDELLTRA (oncology T-cell engagers), and Tezspire (severe asthma co-developed with AstraZeneca). The portfolio also includes a growing biosimilars franchise (AMJEVITA, MVASI, KANJINTI, AVSOLA, RIABNI) and rare disease assets (TAVNEOS, Tepezza, Krystexxa, Uplizna) acquired through the $27.8 billion Horizon Therapeutics acquisition.

Revenue is generated primarily through one-time sales of innovative biologic medicines through traditional pharmaceutical channels: direct sales forces targeting healthcare providers, contracts with hospital buying groups for institutional purchases, specialty pharmacy distribution for cold-chain biologics, and retail pharmacy wholesalers. Direct-to-patient programs (Amgen Now offering Repatha at $238/month for uninsured patients) provide a supplementary distribution and access layer. Manufacturing relies on a capital-intensive, multi-continent network spanning Thousand Oaks, Puerto Rico (the 1.7M sq ft flagship site), Rhode Island, Ohio (opened February 2024), Singapore, Ireland, and the Netherlands, with European headquarters in Zug, Switzerland and R&D centers in Cambridge, South San Francisco, Shanghai, and Hyderabad, India.

The business reaches millions of patients across approximately 100 countries. The pipeline includes 273 ongoing clinical trials and 30 Phase III programs, with MariTide (a GIPR/GLP-1R bispecific agonist for obesity) representing the most consequential late-stage asset targeted at a market where 90% of obesity remains untreated. Notable risks include regulatory scrutiny of TAVNEOS (FDA proposing withdrawal and EMA recommending revocation due to clinical trial data integrity issues inherited from ChemoCentryx), generic and biosimilar erosion of legacy franchises, and pricing pressure exemplified by Colorado's attempt to cap Enbrel at $31,200/year.

Name

Amgen

Legal name

Amgen Inc.

Website

https://amgen.com

Company type

Public

Founded year

1980

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Amgen is a global independent biotechnology company headquartered in Thousand Oaks, California, that discovers, develops, manufactures, and commercializes biologic medicines across cardiovascular, oncology, inflammation, bone health, and rare disease therapeutic areas, serving millions of patients in approximately 100 countries worldwide.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Biologics & Biosimilars Distributors (HLAIAJAH)

Keywords

• Biologic medicines manufacturing
• Oncology therapeutics development
• Cardiovascular disease treatments
• Rare disease pharmaceuticals
• Biosimilar drug production

Headquarters

HQ city

Thousand Oaks

HQ country

United States

HQ region

North America

Offices14 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure, Personnel

Revenue model

1. Specialty Pharmaceutical Sales: Amgen generates revenue primarily through the sale of innovative biologic medicines that treat serious illnesses. The company focuses on drugs for cardiovascular disease, rare diseases, inflammatory conditions, and cancer.
2. Biosimilar Sales: Amgen commercializes biosimilar medicines including AMJEVITA (adalimumab-atto), MVASI (bevacizumab-awwb), KANJINTI (trastuzumab-anns), AVSOLA (infliximab-axxq), and RIABNI (rituximab-arrx) as biosimilars to reference products.
3. Direct-to-Patient Programs: Amgen operates Amgen Now program offering Repatha at $238 per month for uninsured patients, demonstrating direct patient access programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Amgen discovers, develops, manufactures, and commercializes biologic medicines and small molecule therapies for serious illnesses across four therapeutic areas: cardiovascular/metabolic disease, bone health, inflammation, and oncology, with an expanded rare disease franchise following the Horizon Therapeutics acquisition. The company's portfolio includes innovative brands such as Repatha, Prolia, Enbrel, BLINCYTO, KYPROLIS, LUMAKRAS, IMDELLTRA, and Tezspire, alongside a growing biosimilars business (AMJEVITA, MVASI, KANJINTI, AVSOLA, RIABNI). Amgen also operates direct-to-patient access programs and pipeline candidates including the obesity therapy MariTide.

Product overview

Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative medicines across four therapeutic areas: general medicine (cardiovascular, obesity, bone health), rare disease, inflammation, and oncology. The company operates a diversified portfolio of core products including biologic medicines (EPOGEN, NEUPOGEN, Enbrel, Prolia, XGEVA, Repatha), oncology treatments (BLINCYTO, KYPROLIS, LUMAKRAS, IMDELLTRA), inflammation therapies (Tezspire, Otezla), and rare disease medicines (TAVNEOS, UPLIZNA, TEPEZZA). Following acquisitions of Horizon Therapeutics (2023) and ChemoCentryx (2022), Amgen expanded into rare diseases with TEPEZZA for thyroid eye disease and Krystexxa for gout. The company also maintains a growing biosimilars business (AMJEVITA, MVASI, KANJINTI, AVSOLA, RIABNI). The pipeline includes MariTide for obesity. Amgen operates across approximately 100 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• IMDELLTRA (tarlatamab): T-cell engager therapy for extensive-stage small cell lung cancer (ES-SCLC), approved by FDA in May 2024 and by European Commission in June 2026.
• IMDYLLTRA (tarlatamab)
• Repatha (evolocumab)
• Enbrel (etanercept)
• Prolia (denosumab)
• TEZSPIRE (tezepelumab)
• UPLIZNA (inebilizumab)
• TAVNEOS (avacopan)
• Tepezza (teprotumumab)
• Krystexxa (pegloticase)
• MariTide
• BLINCYTO (blinatumomab)
• LUMAKRAS (sotorasib)
• Kyprolis (carfilzomib)
• Nplate (romiplostim)
• Corlanor (ivabradine)
• Sensipar/Mimpara (cinacalcet)
• EVENITY (romosozumab)
• Parsabiv (etelcalcetide)
• Vectibix (panitumumab)
• Aranesp (darbepoetin alfa)
• Neulasta (pegfilgrastim)
• EPOGEN (epoetin alfa)
• NEUPOGEN (filgrastim)
• IMJUDIA / AMJEVITA
• Biosimilars portfolio
• LabXchange
• Amgen Scholars
• Breakaway from Cancer

Products and services

• EPOGEN (epoetin alfa)
• NEUPOGEN (filgrastim)
• Neulasta (pegfilgrastim)
• Enbrel (etanercept)
• Repatha (evolocumab)
• Prolia (denosumab)
• XGEVA (denosumab)
• EVENITY (romosozumab)
• Tezspire (tezepelumab)
• Otezla (apremilast)
• BLINCYTO (blinatumomab)
• KYPROLIS (carfilzomib)
• LUMAKRAS (sotorasib)
• IMDELLTRA (tarlatamab-dlle)
• Vectibix (panitumumab)
• Nplate (romiplostim)
• Corlanor (ivabradine)
• Sensipar/Parsabiv (cinacalcet/etelcalcetide)
• Aimovig (erenumab)
• TEPEZZA (teprotumumab)
• Krystexxa (pegloticase)
• TAVNEOS (avacopan)
• UPLIZNA (inebilizumab)
• AMJEVITA (adalimumab-atto)
• MVASI (bevacizumab-awwb)
• KANJINTI (trastuzumab-anns)
• AVSOLA (infliximab-axxq)
• RIABNI (rituximab-arrx)
• MariTide (maridebart cafraglutide)
• Amgen Now Patient Assistance Program

Quantifiable outcome

• Repatha reduced risk of major cardiovascular events by 29% in high-risk diabetes patients
• +2 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core, minor and regional.

• OpenAIcoreTechnology or Integration · 25 June 2026Amgen is partnering with OpenAI as part of GPT-Rosalind launch for life sciences research, applying AI models across scientific workflows.
• AstraZenecacoreTechnology or Integration · 25 June 2026AstraZeneca and Amgen are currently piloting FDA's real-time clinical trial monitoring approach, streaming live clinical data into FDA review systems.
• FDAcoreStrategic or Co-development Partner · 1 January 2026Amgen is piloting FDA's real-time clinical trial monitoring program, streaming live clinical data directly into FDA review systems through an AI-powered cloud platform.
• FIFA World Cup 2026minorGTM or Marketing Partner · 1 January 2026Official biotech partner of Los Angeles Host Committee for FIFA World Cup 2026, reaching global audience of 6 billion people.
• Amgen India - HyderabadminorOthers · 1 January 2026Technology and innovation center in Hyderabad expanding digital, data science, and AI capabilities as part of global technology operations.
• Kissei PharmaceuticalregionalChannel Partner/ Reseller/ Distributor · 1 January 2022Distribution partner for Tavneos in Japan. Has reported 20 deaths among Japanese patients on the drug.
• AstraZenecacoreStrategic or Co-development Partner · 17 December 2021Co-development and co-commercialization of Tezspire (tezepelumab) for severe asthma. AstraZeneca provides global commercialization capabilities while Amgen leads manufacturing.
• CSL ViforcoreChannel Partner/ Reseller/ Distributor · 1 January 2021CSL commercializes TAVNEOS outside the U.S. under collaboration with Vifor Fresenius Medical Care Renal Pharma. European rights held by CSL's Vifor.
• BeiGenecoreStrategic or Co-development Partner · 2 January 2020Strategic collaboration to expand Amgen's oncology presence in China. BeiGene provides local market expertise and commercial infrastructure for Amgen's oncology portfolio in China.
• Amgen-Betta Pharmaceuticals Joint VentureregionalStrategic or Co-development Partner · 1 January 2013Joint venture established in China for commercialization of Amgen medicines in the Chinese market.
• Amgen Astellas BioPharma K.K.regionalStrategic or Co-development Partner · 1 January 2013Alliance in Japan for development and commercialization of medicines. Became wholly-owned affiliate in 2020, renamed Amgen K.K.
• ServierminorStrategic or Co-development Partner · 1 January 2011Collaboration obtaining U.S. commercial rights to ivabradine for cardiovascular treatments.

Scale indicators13 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Eli Lilly: Eli Lilly is a major global biopharmaceutical company with overlapping therapeutic areas including cardiometabolic, oncology, immunology, and rare disease. Lilly is the most direct competitor in obesity via Mounjaro/Zepbound, where Amgen is positioning MariTide. Both companies operate large-scale biologic manufacturing and pursue AI-driven R&D.
• Regeneron Pharmaceuticals: Regeneron is a science-driven biotech with a biologic-heavy portfolio including Eylea, Dupixent (with Sanofi), and Libtayo. Highly comparable to Amgen in monoclonal antibody expertise, biotech origin, and innovation pipeline, with overlap in ophthalmology/rare disease versus Amgen's TEPEZZA and inflammation franchises.
• Vertex Pharmaceuticals: Vertex is a global biotechnology company specializing in serious diseases with a focus on small-molecule and biologic therapies for cystic fibrosis, pain, and rare diseases. Comparable to Amgen as a similarly scaled, R&D-intensive biotech, particularly relevant given Amgen's rare disease expansion via Horizon (CF overlap in CFTR-modulator-adjacent diseases).
• Biogen: Biogen is a biotechnology company focused on serious neurological, autoimmune, and rare diseases with a biologic-heavy portfolio. Comparable to Amgen in biotech origin, biologic manufacturing capability, and rare-disease strategic focus, particularly relevant given Amgen's UPLIZNA (NMOSD/IgG4 disease) and TAVNEOS (vasculitis) franchises.

Broad incumbents

• Pfizer: Pfizer is one of the largest global biopharmaceutical companies with a similarly diversified portfolio spanning oncology, inflammation, vaccines, and rare disease. Pfizer's broad specialty/biologic pipeline and global commercial footprint make it a direct comparison point for Amgen's diversified specialty pharma model and post-Horizon scale.
• Merck & Co. Merck operates a large R&D-driven pharmaceutical business with deep oncology, vaccines, and specialty portfolios. Comparable to Amgen in scale, biologics capability, and global commercial reach, particularly in oncology where both compete (Amgen's LUMAKRAS, IMDELLTRA versus Merck's Keytruda).
• Bristol Myers Squibb: Bristol Myers Squibb is a diversified specialty biopharma with a large oncology and immunology portfolio. Comparable to Amgen in biologics focus, oncology pipeline depth (BLINCYTO/IMDELLTRA versus BMS hematology assets), and the post-LOE diversification strategy Amgen is pursuing with Horizon.
• AbbVie: AbbVie is a global biopharmaceutical company with major franchises in immunology, oncology, and neuroscience. Highly comparable to Amgen in biologics-heavy portfolio mix, large-acquisition growth strategy (Humira heritage, Allergan integration), and biosimilar exposure as Humira faces AMJEVITA and other biosimilars including Amgen's.
• Johnson & Johnson Innovative Medicine: J&J Innovative Medicine is a diversified biopharma with deep immunology, oncology, and pulmonary hypertension franchises. Comparable to Amgen in scale, R&D intensity, and global commercial reach; J&J's Stelara/Tremfya overlap with Enbrel/Tezspire in immunology, while its oncology pipeline overlaps Amgen's.
• Gilead Sciences: Gilead is a biopharmaceutical company with a diversified specialty portfolio in HIV, oncology, and inflammation. Comparable to Amgen in scale and biologics orientation, with overlap in inflammation/immunology (Gilead's post-Celgene assets) and oncology (BLINCYTO/IMDELLTRA versus Gilead's Trodelvy).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/amgen
• YouTubeyoutube.com/user/Amgen
• Facebookfacebook.com/amgenbiotech
• LinkedInlinkedin.com/company/amgen
• Instagraminstagram.com/amgenbiotech
• TikToktiktok.com/@amgenbiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries13 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A27 records

Investments19 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amgen